ALK1FLT1-Fc

ALK1FLT1-Fc is a recombinant fusion protein designed as a dual ligand trap that targets and sequesters both vascular endothelial growth factor (VEGF) and bone morphogenetic proteins 9 and 10 (BMP-9/10), thereby inhibiting pro-angiogenic signaling pathways. The molecule consists of the extracellular domains of ALK1 (activin receptor-like kinase 1) fused to the Fc region of an IgG, combined with the VEGF receptor 1 (FLT1 or VEGFR1) Fc fusion. Preclinical data show potent inhibition of both VEGF-induced and BMP-9/10-induced angiogenesis, resulting in significant reduction in tumor growth and angiogenesis in in vivo models[1][3]. The drug is being investigated as an anti-angiogenic therapy for cancer, with demonstrated activity in multiple tumor models.